eXoZymes (EXOZ)
Develops AI-assisted enzymes for making small molecules in cell-free bioreactors.
Something off on this page? Send us feedback.
Develops AI-assisted enzymes that operate outside living cells to turn feedstocks into small molecules. Its development-stage biosolutions target potential pharmaceutical ingredients, nutraceuticals, and fuels.
Engineers AI-assisted enzymes for cell-free bioreactors that convert feedstocks into small molecules. The company describes these systems as biosolutions. The resulting biosolutions target potential pharmaceutical ingredients, nutraceuticals, and fuels rather than a mature product catalog. The platform is rooted in enzyme systems designed to operate outside living cells.
Based in Monrovia, California, the small, R&D-heavy company combines founder scientific leadership with a CEO installed shortly before its IPO. Commercial progress depends on scaling the technology and executing with partners. Its public materials frame current work around NCT and biomanufacturing applications.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.7M · Total debt $1.1M · Total assets $8.0M · Shareholders' equity $3.7M
- Revenue
- $0
- Operating income
- −$3.0M
- Net income
- −$2.9M
No dividends on record.
| Institutions | 1.34% | 124.6K shares | |
|---|---|---|---|
| 10 holders · as of Jun 30, 2026 | |||
| Insiders | 40.00% | 3.71M shares | |
| 9 holders · as of Sep 2, 2026 | |||
| Other | 58.66% | 5.44M shares | |
| remainder | |||
9.28M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Tyler KormanInsider | 8.97% | 832,569 | filed Nov 18, 2024 |
Tyler Paz KormanInsiderofficer: Chief Scientific Officer | 8.22% | 762,837 | filed Aug 25, 2026 |
Paul OpgenorthInsider | 8.02% | 744,333 | filed Nov 18, 2024 |
Paul Hideo OpgenorthInsiderofficer: Vice President, Development | 6.95% | 645,149 | filed Apr 8, 2026 |
James U BowieInsider | 6.44% | 597,388 | filed Nov 18, 2024 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Michael Heltzen | officer: Chief Executive Officer | +350 | $7.51 |
| Aug 26, 2026 | Michael Heltzen | officer: Chief Executive Officer | +505 | $7.48 |
| Apr 9, 2026 | Tyler Paz Korman | officer: Chief Scientific Officer | −750 | $10.53 |
| Apr 8, 2026 | Tyler Paz Korman | officer: Chief Scientific Officer | −750 | $10.04 |
- Codexis
Directed-enzyme engineering for scalable therapeutic manufacturing
- LanzaTech Global
Carbon-to-chemicals and fuel production through gas fermentation
- Ginkgo Bioworks
Cell-programming platform for industrial and biopharma applications
- Twist Bioscience
Synthetic-biology platform spanning DNA, RNA, proteins, and discovery
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| eXoZymes | $6.26 | +1.95% | $57.0M | — | — | — | — |
| Codexis | $1.42 | +2.54% | $148.4M | — | — | 1.9 | −2.7% |
| LanzaTech Global | $6.26 | +2.91% | $13.4M | 0.1 | — | 0.2 | −0.8% |
| Ginkgo Bioworks | $8.90 | +11.53% | $521.3M | — | — | 4.7 | −59.4% |
| Twist Bioscience | $166.92 | +0.66% | $10.33B | — | — | 23.9 | +23.3% |
| Median | 0.1 | — | 3.3 | −1.7% |